(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)
For APOE4 carriers specificallywho show accelerated mitochondrial dysfunctionthis pathway represents a mechanistically rational intervention target
A change in clarity is generally the most reliable early sign, since a properly reconstituted and well-stored solution should remain visually consistent throughout its usable life
Grivennikov, S
10.1152/ajpendo.00236.2023
Achilles Tendon-to-Bone Healing Krivic et al., Journal of Orthopaedic Research (2006) Krivic and colleagues, working at the Laboratory for Experimental Surgery at the University of Zagreb Medical School, conducted a controlled rat study examining BPC-157s effect on Achilles tendon-to-bone healing
